[go: up one dir, main page]

NO20090328L - Nye forbindelser 385 - Google Patents

Nye forbindelser 385

Info

Publication number
NO20090328L
NO20090328L NO20090328A NO20090328A NO20090328L NO 20090328 L NO20090328 L NO 20090328L NO 20090328 A NO20090328 A NO 20090328A NO 20090328 A NO20090328 A NO 20090328A NO 20090328 L NO20090328 L NO 20090328L
Authority
NO
Norway
Prior art keywords
compound
present
new connections
relates
formula
Prior art date
Application number
NO20090328A
Other languages
English (en)
Norwegian (no)
Inventor
Dominika Turek
Didier Rotticci
Tobias Rein
Fernando Huerta
Karin Staaf
Jeremy Burrows
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090328(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090328L publication Critical patent/NO20090328L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20090328A 2006-06-27 2009-01-21 Nye forbindelser 385 NO20090328L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81675506P 2006-06-27 2006-06-27
PCT/SE2007/000621 WO2008002245A2 (fr) 2006-06-27 2007-06-26 Nouveaux composés 385

Publications (1)

Publication Number Publication Date
NO20090328L true NO20090328L (no) 2009-01-26

Family

ID=38846128

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090328A NO20090328L (no) 2006-06-27 2009-01-21 Nye forbindelser 385

Country Status (19)

Country Link
US (1) US20080188503A1 (fr)
EP (1) EP2046783A4 (fr)
JP (1) JP2009542639A (fr)
KR (1) KR20090024295A (fr)
CN (1) CN101511824A (fr)
AR (1) AR061653A1 (fr)
AU (1) AU2007265732A1 (fr)
BR (1) BRPI0713578A2 (fr)
CA (1) CA2655444A1 (fr)
CL (1) CL2007001882A1 (fr)
EC (1) ECSP088974A (fr)
IL (1) IL195665A0 (fr)
MX (1) MX2008015721A (fr)
NO (1) NO20090328L (fr)
RU (1) RU2008148903A (fr)
TW (1) TW200815417A (fr)
UY (1) UY30438A1 (fr)
WO (1) WO2008002245A2 (fr)
ZA (1) ZA200810577B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1934213A1 (fr) 2005-09-30 2008-06-25 Astra Zeneca AB Imidazo[1,2-a] pyridine à activité anti-prolifération cellulaire
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2419425A4 (fr) 2009-04-15 2012-08-29 Astrazeneca Ab Pyrimidines substituées par imidazole utiles dans le traitement de troubles liés à la glycogène synthase kinase 3, tels que la maladie d'alzheimer
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012050517A1 (fr) * 2010-10-14 2012-04-19 Astrazeneca Ab Pyrimidine substituée par imidazole ayant une puissance élevée d'inhibition de la gsk3 ainsi qu'une sélectivité pan-kinases
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP3169337A1 (fr) 2014-07-17 2017-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le traitement de maladies liées à la jonction neuromusculaire
WO2016207366A1 (fr) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement d'infections virales
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (fr) 2019-02-15 2020-08-20 Incyte Corporation Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
WO2020180959A1 (fr) 2019-03-05 2020-09-10 Incyte Corporation Composés de pyrazolyl pyrimidinylamine en tant qu'inhibiteurs de cdk2
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
KR102206111B1 (ko) 2019-04-01 2021-01-22 박광호 목욕탕용 담수 및 해수 가열시스템
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
CA3150681A1 (fr) 2019-08-14 2021-02-18 Incyte Corporation Composes imidazolyl-pyrimidinylamines utilises comme inhibiteurs de la cdk2
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
AU2022215725A1 (en) * 2021-02-05 2023-09-14 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Cdk inhibitor
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
EP1554269A1 (fr) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles et thiazoles presentant des activites d'inhibition des proteines kinases
EP1648887A1 (fr) * 2003-07-30 2006-04-26 Cyclacel Limited Derives de pyridinylamino-pyrimidine utiles comme inhibiteurs de la proteine kinase
AU2004285745A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
JP2008524191A (ja) * 2004-12-17 2008-07-10 アストラゼネカ アクチボラグ Ｃｄｋ阻害剤としての４−（４−（イミダゾール−４−イル）ピリミジン−２−イルアミノ）ベンズアミド
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I

Also Published As

Publication number Publication date
KR20090024295A (ko) 2009-03-06
RU2008148903A (ru) 2010-08-10
EP2046783A4 (fr) 2010-08-04
JP2009542639A (ja) 2009-12-03
ECSP088974A (es) 2009-01-30
BRPI0713578A2 (pt) 2012-10-23
AR061653A1 (es) 2008-09-10
WO2008002245A3 (fr) 2008-02-14
EP2046783A2 (fr) 2009-04-15
ZA200810577B (en) 2009-08-26
US20080188503A1 (en) 2008-08-07
WO2008002245A8 (fr) 2008-10-09
AU2007265732A1 (en) 2008-01-03
CN101511824A (zh) 2009-08-19
TW200815417A (en) 2008-04-01
IL195665A0 (en) 2009-09-01
WO2008002245A2 (fr) 2008-01-03
CL2007001882A1 (es) 2008-02-08
MX2008015721A (es) 2009-01-08
UY30438A1 (es) 2008-01-31
CA2655444A1 (fr) 2008-01-03

Similar Documents

Publication Publication Date Title
NO20090328L (no) Nye forbindelser 385
NO20090327L (no) Nye forbindelser 384
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20082496L (no) Pyrazinderivater
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20091560L (no) Biaryleterureaforbindelser
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20092033L (no) Nye forbindelser
MY138906A (en) Phenyl derivatives as ppar agonists
NO20074703L (no) Antibakterielle piperidinderivater
TW200745111A (en) New compounds
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
NO20091185L (no) Piperidinderivater
MX2009013501A (es) Compuestos piperidinicos y sus usos.
NO20055977L (no) Nye benzimidazolderivater
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application